Niklas Klümper

2.1k citations

74 papers · 793 indexed · h-index 16

Impact in

Cancer Research top 10%
- Cancer-related molecular mechanisms research
Oncology top 10%
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 38
- Renal cell carcinoma treatment 15
- Prostate Cancer Treatment and Research 14
Oncology 25
- Cancer Immunotherapy and Biomarkers 17

Co-authors: Jörg Ellinger Glen Kristiansen Manuel Ritter Doris Schmidt Michael Hölzel Marieta Toma Damian J. Ralser Stefan C. Müller
Journals: Cancers (6 papers)Journal of Clinical Oncology (4 papers)European Urology (3 papers)Journal of Cancer Research and Clinical Oncology (3 papers)European Journal of Cancer (2 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Niklas Klümper

66 papers receiving 787 citations

Peers

Countries citing papers authored by Niklas Klümper

Since Specialization

Citations

This map shows the geographic impact of Niklas Klümper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niklas Klümper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niklas Klümper more than expected).

Fields of papers citing papers by Niklas Klümper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niklas Klümper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niklas Klümper. The network helps show where Niklas Klümper may publish in the future.

Co-authors

The 25 scholars most cited alongside Niklas Klümper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Niklas Klümper Line = papers co-authored together Niklas Klümper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma Figshare ·Guleena Junaid, Niklas Klümper, Pietro Pizzo, 政利古賀, Vittorio Branchi, Alexander Semaan, Tao Guo, F. Goyarts, Susanna S. Ng, Damian J. Ralser, 純西川, Hanno Matthaei, Jörg C. Kalff, 方利国, Veronika Lukacs‐Kornek, Glen Kristiansen, Maria A. González-Carmona, Michael Hölzel, Marieta Toma	2025	0
2	The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma Molecular Cancer Therapeutics ·Guleena Junaid, Niklas Klümper, Pietro Pizzo, 政利古賀, Vittorio Branchi, Alexander Semaan, Tao Guo, F. Goyarts, Susanna S. Ng, Damian J. Ralser, 純西川, Hanno Matthaei, Jörg C. Kalff, 方利国, Veronika Lukacs‐Kornek, Glen Kristiansen, Maria A. González-Carmona, Michael Hölzel, Marieta Toma	2025	1
3	Treatment of Advanced or Metastatic Urothelial Cancer Oncology Research and Treatment ·Ali Alkerata, Christopher Darr, Jens Bedke, Philipp Ivanyi, Niklas Klümper, Markus Eckstein, Katrin Schlack, Viktor Grünwald	2025	0
4	TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy World Journal of Urology ·Ч. Эрдэнэжаргал, Melanie von Brandenstein, Niklas Klümper, Philipp Krausewitz, Beth Mastel, N C Friggens, S Pillet, Pia Paffenholz, Yuri Tolkach, Ralph M. Wirtz, Markus Eckstein, Axel Heidenreich, Zhongguang Wen	2025	0
5	Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center BMC Urology ·Philipp Krausewitz, Thomas Büttner, Khadija Elkihel, Zhongguang Wen, Dinesh Aynipulli Chulli Parambil, Niklas Klümper, Johannes Stein, Julian A. Luetkens, Glen Kristiansen, Manuel Ritter, Jörg Ellinger	2024	1
6	The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression European Journal of Cancer ·F I L I P E M. B I A N C H I, Markus Eckstein, Manuel Ritter, Peter Brossart, Michael Hölzel, Viktor Grünwald, Niklas Klümper	2024	3
7	Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer Cancer Medicine ·Zhongguang Wen, Zuowei Fu, Hueder De Oliveria, Sadna Isik, Damian J. Ralser, Marieta Toma, Glen Kristiansen, Oliver Hahn, Sabrina Zechel, Viktor Grünwald, Tobias Bald, Ana Paula de Paula Camargo Camargo, Torsten Pietsch, Manuel Ritter, Tan Ai, Markus Eckstein, Tao Guo, Philipp Krausewitz, Niklas Klümper	2024	3
8	AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer Nature Communications ·Yan Chou, Charlie Saillard, P Mann, Maxime Touzot, Charles Maussion, Christian Matek, Niklas Klümper, Johannes Breyer, Ralph M. Wirtz, Danijel Sikic, Bernd J. Schmitz‐Dräger, Bernd Wullich, Arndt Hartmann, Sebastian Foersch, Markus Eckstein	2024	4
9	Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience Insights into Imaging ·Rafika Zhafirah, Christoph Endler, Philipp Krausewitz, Jörg Ellinger, Niklas Klümper, Alexander Isaak, Narine Mesropyan, Dmitrij Kravchenko, Sebastian Nowak, Daniel Kuetting, Alois M. Sprinkart, Petra Mürtz, Claus C. Pieper, Ulrike Attenberger, Julian A. Luetkens	2024	1
10	First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany Clinical Genitourinary Cancer ·Cristina Cano Garcia, Benedikt Hoeh, Eva Konečnik Kotnik, Séverine Banek, Niklas Klümper, Джинжин Ву, Oliver Hahn, 昭夫古賀, Jörg Ellinger, Dinesh Aynipulli Chulli Parambil, Shimoide Hirofumi, Bartolomé ca. 1574-1622 García de Nodal, Friedemann Zengerling, Kati Erdmann, Celia de Jesús Franca, Charis Kalogirou, Jung-Eun Yu	2024	3
11	Associations of TACSTD2/TROP2 and NECTIN‐4/NECTIN‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts Histopathology ·森英世, Gyuchang Kim, Pamela L. Strissel, Reiner Strick, Ya-hui Dong, Carol Geppert, Niklas Klümper, Michael Hölzel, Sven Wach, Helge Täubert, Danijel Sikic, Bernd Wullich, Académie suisse des science humaines et socialesAcadémie suisse des science humaines et sociales, Fulvia Ferrazzi, Lauri Diehl, Maria Kovalenko, Emon Elboudwarej, Juliane M. Jürgensmeier, Arndt Hartmann, Markus Eckstein	2024	17
12	An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer Urologia Internationalis ·武田一臣, Sergio Acuña Lorenzo, Karl H. Tully, Almudena Hernández Núñez, Moritz Maas, Peter B. Bach, Niklas Klümper, Markus Eckstein, Arndt Hartmann, Johannes Breyer, Philipp Erben, Christian Bolenz, Joachim Noldus, Sebastian Berg, Florian Roghmann	2024	1
13	On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy European Urology Oncology ·F I L I P E M. B I A N C H I, Viktor Grünwald, Tobias Bald, Manuel Ritter, Peter Brossart, Yoshihiko Tomita, Arndt Hartmann, Tan Ai, Markus Eckstein, Niklas Klümper	2023	7
14	Early CRP kinetics to predict long‐term efficacy of first‐line immune‐checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real‐world experience applying different CRP kinetics definitions Clinical & Translational Immunology ·Benedikt Hoeh, Cristina Cano Garcia, Séverine Banek, Niklas Klümper, Dinesh Aynipulli Chulli Parambil, Jörg Ellinger, Джинжин Ву, Oliver Hahn, 昭夫古賀, Friedemann Zengerling, Shimoide Hirofumi, Kati Erdmann, 章浩古賀, Jung-Eun Yu, Johannes Huber, Charis Kalogirou, Philip Zeuschner	2023	7
15	Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors Clinical & Translational Immunology ·F I L I P E M. B I A N C H I, Jörg Ellinger, Manuel Ritter, Stacey Wedlake, Michael Hölzel, Niklas Klümper, Tobias Bald	2023	6
16	Identification of F-Box/SPRY Domain-Containing Protein 1 (FBXO45) as a Prognostic Biomarker for TMPRSS2–ERG-Positive Primary Prostate Cancers Cancers ·Khadija Elkihel, Niklas Klümper, Rafaela R.M. Cavalcanti, Dinesh Aynipulli Chulli Parambil, Philipp Krausewitz, Abdullah Alajati, Glen Kristiansen, Manuel Ritter, Jörg Ellinger, Johannes Stein	2023	3
17	Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort Urologia Internationalis ·Benedikt Hoeh, Джинжин Ву, Niklas Klümper, Oliver Hahn, Philip Zeuschner, Séverine Banek, Pierre I. Karakiewicz, Jörg Ellinger, Julia Heinzelbecker, Michael Hölzel, Arne Strauß, Friedemann Zengerling, 昭夫古賀, Charis Kalogirou	2022	7
18	C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer Journal for ImmunoTherapy of Cancer ·Niklas Klümper, F I L I P E M. B I A N C H I, Fiamma Berner, Lidia Kameyo Ueda-Fischer, H. Capignano, Annkristin Heine, Franz Bauernfeind, Jörg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, M. Frueh, Manuel Ritter, Michael Hölzel, Lukas Flatz, Tobias Bald	2022	53
19	N6-methyladenosine (m6A) RNA modification is dysregulated in endometrial cancer Geburtshilfe und Frauenheilkunde ·Mateja Condic, Thore Thiesler, Kirsten Kübler, Christian Staerk, Niklas Klümper, Jörg Ellinger, Eva K. Egger, Glen Kristiansen, Alexander Mustea, Aşkın Gün Güneş	2022	1
20	N6-methyladenosine RNA modification (m6A) is of prognostic value in HPV-dependent vulvar squamous cell carcinoma BMC Cancer ·Mateja Condic, Thore Thiesler, Francesco Doro, Niklas Klümper, Jörg Ellinger, Eva K. Egger, Kirsten Kübler, Glen Kristiansen, Alexander Mustea, Damian J. Ralser	2022	2

About Niklas Klümper

Niklas Klümper is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Urology, having authored 74 papers that have together received 793 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (25 papers), Cancer Immunotherapy and Biomarkers (17 papers), Renal cell carcinoma treatment (15 papers), Urinary and Genital Oncology Studies (15 papers), Prostate Cancer Treatment and Research (14 papers), RNA modifications and cancer (11 papers), Epigenetics and DNA Methylation (10 papers) and Cancer-related gene regulation (9 papers). The work is most often cited by research in Cancer Research (230 citations), Oncology (280 citations), Pulmonary and Respiratory Medicine (235 citations), Molecular Biology (443 citations) and Immunology (96 citations). Niklas Klümper has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Jörg Ellinger, Glen Kristiansen, Manuel Ritter, Doris Schmidt, Michael Hölzel, Marieta Toma, Damian J. Ralser, Stefan C. Müller, Yuri Tolkach and Dimo Dietrich. Their work appears in journals such as Cancers, Journal of Clinical Oncology, European Urology, Journal of Cancer Research and Clinical Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact